Financial reports
10-K
2019 FY
Annual report
12 Mar 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
28 Feb 19
10-Q
2018 Q3
Quarterly report
7 Nov 18
10-Q
2018 Q2
Quarterly report
8 Aug 18
10-Q
2018 Q1
Quarterly report
8 May 18
10-K
2017 FY
Annual report
27 Feb 18
Current reports
8-K
Menlo Reports Financial Results for Subsidiary Foamix Pharmaceuticals for Year Ended Research and Development Expenses
12 Mar 20
8-K
Entry into a Material Definitive Agreement
10 Mar 20
8-K
Foamix and Menlo Announce Shareholder Approval of Proposed Merger
6 Feb 20
8-K
AMZEEQ is the First FDA Approved Topical Form of Minocycline for the Treatment of Moderate to Severe Acne
14 Jan 20
8-K
Foamix Announces AMZEEQTM(minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne
9 Jan 20
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
18 Dec 19
8-K
Other Events
16 Dec 19
8-K
Entry into a Material Definitive Agreement
4 Dec 19
8-K
Foamix Reports Third Quarter 2019 Financial Results and Provides Corporate Update
12 Nov 19
8-K
Entry into a Material Definitive Agreement
12 Nov 19
Registration and prospectus
15-12B
Securities registration termination
19 Mar 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 20
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 20
POS AM
Prospectus update (post-effective amendment)
18 Mar 20
25-NSE
Exchange delisting
9 Mar 20
425
Business combination disclosure
3 Mar 20
425
Business combination disclosure
28 Feb 20
425
Business combination disclosure
6 Feb 20
Proxies
DEFA14A
Additional proxy soliciting materials
28 Jan 20
DEFA14A
Additional proxy soliciting materials
10 Jan 20
DEFM14A
Proxy related to merger
7 Jan 20
DEF 14A
Definitive proxy
11 Mar 19
PRER14A
Preliminary revised proxy
8 Mar 19
PRE 14A
Preliminary proxy
1 Mar 19
DEF 14A
Definitive proxy
11 Apr 18
Other
EFFECT
Notice of effectiveness
23 Mar 20
CORRESP
Correspondence with SEC
8 Mar 19
UPLOAD
Letter from SEC
8 Mar 19
UPLOAD
Letter from SEC
5 Mar 19
EFFECT
Notice of effectiveness
12 Apr 18
CORRESP
Correspondence with SEC
10 Apr 18
UPLOAD
Letter from SEC
10 Apr 18
EFFECT
Notice of effectiveness
14 Mar 17
CORRESP
Correspondence with SEC
10 Mar 17
UPLOAD
Letter from SEC
3 Mar 17